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Abstract
Background: Hereditary Tyrosinemia type 1 (HT1) is a rare metabolic disorder caused by a defect in the enzyme
Fumarylacetoacetate Hydrolase. Due to this defect, toxic products accumulate which, in turn, cause liver and kidney
dysfunction. Treatment with 2-(2-nitro-4-trifluoromethylbenoyl)-1,3-cyclohexanedione (NTBC) and diet has diminished
these problems, but recent data indicate that HT1 patients have neurocognitive problems. However, the
neuropsychological profile of these patients is unknown. Therefore, this study aimed to investigate this
neuropsychological profile by comparing HT1 patients with healthy controls.
Methods: Neurocognitive testing was performed in a heterogeneous group of 19 NTBC and dietary treated
HT1 patients (five female, fourteen male; mean age 12.9 ± 4.8 years; range 7.9–23.6 years) and 19 age and
gender matched controls (five female, fourteen male; mean age 13.2 ± 4.6 years; range 8.1–24.8 years). IQ
scores were estimated and all participants performed the Amsterdam Neuropsychological Tasks, measuring
executive functions (inhibition, cognitive flexibility and working memory) and social cognition (face recognition
and identification of facial emotions).
Results: HT1 patients showed poorer estimated IQ, executive functioning (working memory and cognitive
flexibility), and social cognition compared to healthy controls. Lower IQ scores in HT1 patients were mostly
unrelated to scores on executive function- and social cognition tasks and therefore did not account for group
differences in these domains. Further analyses within the HT1 patient group (comparing different groups of
patients based on the age at diagnosis and the clinical symptoms at diagnosis) did not reveal any significant
results. The duration of NTBC treatment was negatively correlated with IQ.
Conclusions: Despite the heterogeneity of the patient group, these data clearly show that IQ, executive
functioning and social cognition are affected in HT1 patients, and that IQ screening is not sufficient for
cognitive monitoring of these patients. Further research should focus on the underlying pathophysiological
mechanisms of these impairments to consequently try to improve treatment strategies.
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Background
Hereditary Tyrosinemia Type 1 (HT1; McKusick 27670)
is an inborn error of tyrosine metabolism, caused by a
deficiency of the enzyme Fumarylacetoacetate Hydrolase.
Due to this defect, toxic products such as maleylacetoa-
cetate, fumarylacetoacetate and succinylacetone are ac-
cumulating. These products cause severe liver
dysfunction, renal tubulopathy, porphyria like syndrome,
cardiomyopathy and hepatocellular carcinoma early in
life [1]. In the past, life expectancy was rather low and
many patients needed a liver transplantation [2]. This
changed after 1992, when a new treatment option be-
came available, called 2-(2-nitro-4-trifluoromethylbe-
noyl)-1,3-cyclohexanedione (NTBC) [3]. NTBC is an
herbicide that blocks the catabolism of tyrosine up-
stream of the initial enzymatic defect, preventing the
formation of the toxic products mentioned before. With
this treatment, liver failure, renal tubulopathy, cardiomy-
opathy and porphyria like syndrome resolved and the life
expectancy strongly increased, while the risk of liver
cancer largely decreased [4, 5]. Despite the success of
NTBC in combination with dietary treatment, current
research suggests suboptimal neurocognitive outcome in
HT1 patients, including reports of a lower IQ, school
problems, and impaired motor control [6–10].
This more or less resembles the history of another
metabolic disorder, namely Phenylketonuria (PKU). In
PKU, the defect is in the conversion of phenylalanine to
tyrosine, leading to an opposite biochemical profile with
high blood phenylalanine and somewhat low blood tyro-
sine concentrations. At first sight, there is no clinical re-
semblance between PKU and HT1. Untreated PKU is
characterized by severely diminished mental develop-
ment, seizures and behavioural difficulties. However,
both diseases have been associated with a suboptimal
neurocognitive outcome despite appropriate treatment,
which in both cases, involves manipulation of phenyl-
alanine and tyrosine intake and consequently its concen-
trations [1, 11].
In PKU, different studies have shown that impaired ex-
ecutive functioning (EF) (over and above lower IQ) might
aggravate problems with other aspects of cognition (e.g.
motor function, visuo-perceptual abilities) [12, 13], and
might underlie problems in other domains as well (e.g. so-
cial functioning, behaviour problems and quality of life)
[14–16]. Next to the impairments in EF, recent research
from our group has shown that PKU patients exhibit spe-
cific difficulties in social cognition, which, in turn, is also re-
lated to social functioning and behaviour problems [17].
This information about EF and social cognition is lacking
in HT1. Therefore, this study aimed to investigate the
neuropsychological profile, including IQ, core EF and as-
pects of social cognition, of HT1 patients, and to compare
these cognitive outcomes with those of healthy controls.
Methods
Patients
Nineteen NTBC and dietary treated HT1 patients (five
female, fourteen male; mean age 12.9 ± 4.8 years; range
7.9–23.6 years), with varying clinical histories and treat-
ment strategies (but excluding those who underwent
liver transplantation) were studied. They were treated in
the Netherlands, UK and Belgium. Phenylalanine and
tyrosine restricted diet was started in all patients directly
after diagnosis. NTBC treatment was started in 18
patients directly after diagnosis. One patient (Table 1,
patient 17) was diagnosed before NTBC became avail-
able and therefore NTBC treatment started after 2 years
of dietary treatment alone. The diet involved natural
protein restriction. Supplementation of all non-
phenylalanine and tyrosine amino acids was provided
with one of the available amino acid mixtures that con-
tain neither phenylalanine nor tyrosine. Nine patients at
some point received phenylalanine supplementation due
to phenylalanine concentrations below the lower target
limit (<30 μmol/L) [18, 19].
Seven of the 19 healthy controls (five female, fourteen
male; mean age 13.2 ± 4.6 years; range 8.1–24.8 years)
were friends/siblings of the HT1 patients, while the
other 12 healthy controls were age and gender matched
only. Some HT1 patients did not complete all tasks.
These patients were excluded from statistical analyses of
these particular tasks only, together with their age and
gender matched controls. Informed consent of all pa-
tients and/or parents was obtained and this study was
approved by the ethics committees of the different clin-
ical centers.
Tests
Neuropsychological assessment was performed by
WGvG and RJ. Assessments took place at the patients’
clinical treatment center. A broad estimation of IQ was
made by using two subtests of the Wechsler Intelligence
Scale for Children Third Edition and Fourth edition
(WISC) for patients from 7 to 16 years old or the
Wechsler Adult Intelligence Scale Third Edition (WAIS)
for patients older than 16 years [20–22]. One perceptual
reasoning subtest (Block Design) and one vocal compre-
hension subtest (Vocabulary) of the WISC or WAIS
were used to estimate performance and verbal IQ,
respectively.
All patients were assessed with the Amsterdam
Neuropsychological Tasks [23], measuring EF and so-
cial cognition. A standardized protocol was used and a
full assessment took up to 3 h to complete. The fol-
lowing EF were measured: inhibitory control (Shifting
Attentional Set-Visual (SSV)), working memory (Feature
Identification (FI) and Memory Search 2D objects (MS2D))
and cognitive flexibility (SSV), together with the following
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two social cognition measurements: Face Recognition (FR)
and Identification of Facial Emotions (IFE) as described by
various study groups [16, 24–26]. In all tasks, both accuracy
and reaction time (RT) were measured. To study RT ad-
equately, baseline speed of the patients was measured and
subtracted from the RT during the different tasks (or task
conditions). In this way, differences in normal RT between
HT1 patients and healthy controls were accounted for.
In the SSV task, patients responded to the movements
of a coloured square across a bar on the computer
screen. They had to respond in accordance (part 1, green
stimulus) or opposite (part 2, red stimulus) to the direc-
tion of the movement of the coloured square. The action
requested of the participants depended on the colour of
the square after each movement (green or red) in part 3.
The contrast between performance in part 1 and 2 rep-
resents inhibitory control, while the contrast between
performances in part 1 and 3 represents cognitive
flexibility.
The MS2D task was used to measure the ability to
maintain an increasing number of stimuli in working
memory. Participants had to search a display consist-
ing of four stimuli, each characterized by two specific
features (colour and shape), for one (part 1) and one
of three target memorized stimuli (part 2). When (one
of ) the target stimuli was present, participants had to
respond with their dominant hand (“yes”-response). If
not, a “no”-response had to be given by using their
non-dominant hand. The contrast between perfor-
mances in part 1 and 2 (with higher working memory
load) represented the working memory-score.
The FI task also measured working memory. Par-
ticipants had to scan a display consisting of four 3x3
matrices that included red elements. The target
stimulus they had to identify was a (memorized)
matrix with three red elements, which were in a
fixed position. The other matrices had fewer red ele-
ments (easy condition) or equal numbers of elements
in different positions (difficult condition). When the
display contained the target stimulus, a “yes”-response was
required.
In the FR task, the ability to recognize neutral faces
was examined. Before each trial, a target face was shown
on the display first for 2.5 s. Thereafter four different
faces were shown and the participant had to judge if the
target individual was presented. If so, a “yes”-response
was required, if not, a “no-response” was required. Three
task parts were performed for this study. In the first task
part, a frontal view of targets and distractors was pro-
vided, in the second part, targets were presented “en
profile” and in the third task part stimuli were presented
upside down.
The IFE task measures the ability to identify emotions
using facial expressions. The expressed emotions in the
four different task parts were respectively happiness,
sadness, anger and fear. When the face on the display
Table 1 Detailed patient characteristics
Time of diagnosis
(months)
Patient Age at diagnosis
(months)
Current age (years) Duration of NTBC
treatment (years)
Clinical problems at diagnosis
≤2 1 0,3 9,2 9,1 pre-symptomatically
2 0,03 14,0 14,0
3 0,03 15,3 15,3
4 0,2 8,1 8,0
5 0,03 15,6 15,6
6 0,1 12,1 12,1
7 0,1 10,3 10,3
8 0,5 10,4 10,4
9 0,1 8,8 8,8
10 1,7 10,4 10,2
2–6 11 3,2 7,9 7,6 Acute liver failure and renal tubulopathy
12 4,1 13,4 13,1 Acute liver failure
13 2,9 9,7 9,5 Acute liver failure
14 3,8 9,9 9,6 Acute liver failure
15 3,0 16,0 15,8 Acute liver failure, renal tubulopathy and rickets
16 5,0 17,7 17,3 Renal tubulopathy, nefromegaly and rickets
≥6 17 8,6 23,4 20,6 Liver cirrhosis
18 13,0 7,9 6,7 Liver cirrhosis
19 38,7 23,6 20,4 Liver cirrhosis, renal tubulopathy and rickets
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showed the target emotion, participants had to use their
dominant hand (“yes”-response). If not, participants had
to use their non-dominant hand (“no”-response).
Statistical analyses
Group differences between HT1 and controls were ana-
lyzed using Mann–Whitney U tests. Non-parametric
tests were used because non-normal and dissimilar dis-
tributions (between groups) were observed for a number
of neuropsychological outcome measures. In order to
find out whether the neuropsychological scores of the
patients fell within or outside the normal range (between
-2SD and +2SD, with negative numbers indicating better
than average accuracy (i.e. lower error rates) or faster
than average speed of responding), we calculated z-
scores by subtracting the mean task score of all healthy
controls from the task score of the patient divided by
the standard deviation of the healthy controls.
As we were also interested in whether potential execu-
tive function and social cognition impairments would be
present over and above (potentially) lower IQ scores in
HT1, additional correlations and group differences be-
tween HT1 patients and controls were studied after de-
letion of all patients (and controls) with IQ-scores
outside the normal range while maintaining the match
on age and gender. To further analyse the heterogeneous
HT1 patient group, groups based on the age at diagnosis
(≤2 months, 2–6 months, ≥6 months) were compared
using the Kruskal Wallis tests. The two-tailed Spearman
correlation analyses were performed to further study a
possible association between the age at diagnosis and
the performance on the neuropsychological tasks. Next
to these analyses, pre-symptomatically and symptomatic-
ally diagnosed patients and patients presenting with and
without liver involvement at diagnosis were compared
using Mann–Whitney U tests. Finally, partial correla-
tions between the duration of NTBC treatment and the
performance on the neuropsychological tasks while cor-
recting for age were performed. In all statistical tests, a
p-value of <0.05 was considered statistically significant.
Analyses were conducted with the statistical program
IBM Statistics 22 (Chicago, Illinois).
Results
Participant characteristics
Descriptive analyses of the HT1 patients showed a large
variation in age at diagnosis and clinical problems. All
patients had received NTBC treatment and a phenyl-
alanine and tyrosine restricted diet for at least 7 years.
Ten patients were diagnosed before 2 months of age,
pre-symptomatically, by selective screening because of
an affected sibling or as a coincidence in the neonatal
PKU screening. The mean age of this group was
11.4 years (range 8.1–15.6 years). Six patients were
diagnosed between 2 and 6 months of age (mean age
12.5 years, range 8.3–17.7), mostly suffering from acute
liver failure and/or renal problems. Three patients were
diagnosed after 6 months of age (mean age 18.3 years,
range 7.9–23.6 years old), all suffering from cirrhosis,
rickets and/or tubular dysfunction (Table 1).
Neurocognitive outcome
Figure 1 shows estimated IQ scores. The median of the es-
timated IQ scores in HT1 patients was 85 (range: 55–111),
with two patients having an estimated IQ between 55 and
65, one patient with an estimated IQ between 65 and 75,
and three patients with an estimated IQ between 75 and
85. All other patients had IQ scores within the normal
range of 85–115. Estimated IQ scores of the healthy
controls were mostly within the normal range, with
four estimated IQ scores above 115. HT1 patients had
significantly lower estimated IQ than healthy controls
(U =60, p < 0.001).
Figure 2 shows EF scores. Part A shows inhibitory
control scores. In the SSV task, there were no significant
differences between HT1 patients and healthy controls
regarding inhibitory control (Percentage errors: U =
153.5, p = 0.435; RT: U = 153, p = 0.435). Part B shows
working memory scores for the different groups. In the
MS2D task, HT1 patients had a significant longer RT
than healthy controls (U = 61, p = 0.003). In the FI task
HT1 patients were also significantly slower than healthy
controls (U = 84, p = 0.013). In addition, HT1 patients
made significantly more mistakes than healthy controls
in this task (U = 98, p = 0.044). Part C shows scores on
cognitive flexibility. The percentage of errors for HT1
patients was significantly higher compared to healthy
controls (U = 95, p = 0.012). No significant differences
for RT were found (U = 170, p = 0.773).
Fig. 1 Estimated IQ scores, comparing HT1 patients and controls.
*p < 0.05, **p < 0.01
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Figure 3 shows scores on social cognition. Part A
shows scores on FR. The percentage of errors for HT1
patients was overall significantly higher when compared
to healthy controls (U = 59.5, p = 0.001). More precisely,
HT1 patients were less accurate than controls on all the
different parts of this task. HT1 patients were also
significantly slower than healthy controls on this task
(U = 93, p = 0.029). A significant difference in RT
was specifically found on the first and second part
of the task (U = 90, p = 0.022 and U = 96, p = 0.037
respectively). Part B shows scores on the IFE. Overall, the
percentage of errors for HT1 patients was significantly
higher compared to healthy controls (U = 72.5, p = 0.012).
More specifically, HT1 patients tended to show a higher
percentage of errors when they had to identify frightened
faces (trend), while a significantly higher percentage of
errors was observed for HT1 patients when they had
to identify happiness (U = 70.5, p = 0.009) and anger
(U = 74.5, p = 0.014). In this task, no significant differ-
ences in RT were found.
Table 2 shows analyses of Z-scores for the different
neuropsychological tasks. Median Z-scores for the HT1-
patients varied between tasks and patients scoring out-
side the normal range were not the same ones in each
task. Overall, between 11 % and 32 % of the patients
have a Z-score > 2 on one or more of the neuropsycho-
logical tasks.
When only selecting the HT1 patients and age- and
gender matched healthy controls with IQ scores
within the normal range (85–115), IQ scores were sig-
nificantly correlated with error percentages FI-working
memory (ρ = −0.49, p = 0.027), and SSV-inhibition
(ρ = −0.55, p = 0.012). Comparing both groups, differences
on FI-working memory became non-significant, while dif-
ferences on SSV-inhibition have not been seen in these ana-
lyses, neither in the previous analyses. However, as IQ was
Fig. 2 Performance on executive functions comparing HT1 patients and controls. Performance is expressed as percentage of errors and/or
reaction time on tasks measuring inhibition a, working memory b and cognitive flexibility c *p < 0.05, **p < 0.01
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not significantly related to any other EF- or social cognition
scores, further group differences could not be explained by
differences in IQ.
When comparing three different groups of HT1 pa-
tients based on the age at diagnosis (<2 months, 2–6
months, >6 months), no significant differences in RT or
the percentage of errors in any of the neuropsychological
tasks were observed. In addition to this, no significant
correlations between the age at diagnosis and task per-
formance were observed. Furthermore, when comparing
pre-symptomatically and symptomatically diagnosed pa-
tients and when comparing patients with or without
liver dysfunction at diagnosis no significant differences
in all the tasks measuring IQ, EF and social cognition
were found. While controlling for age, the duration of
NTBC treatment was significantly negatively correlated
with IQ (r = −0.51, p = 0.046).
Discussion
This is the first controlled HT1 patient study describing
impaired neurocognitive outcome through detailed
neuropsychological testing while comparing them with
age and gender matched healthy controls. The most im-
portant finding was that HT1 patients not only have a
suboptimal outcome on IQ, but more specifically also
appear to have a suboptimal outcome on EF (working
memory and cognitive flexibility) and social cognition
(face recognition and the identification of facial emo-
tions). In most of the tasks measuring EF and social cog-
nition, IQ was not correlated with the outcome
variables, in which cases IQ could therefore not com-
pletely explain the sub optimal outcome on these neuro-
psychological constructs.
Before discussing the results of the study in more de-
tail, one important methodological limitation of the
study has to be addressed. The patient population was
very heterogeneous: patients differed in timing of diag-
nosis and accompanying symptoms. Next to this, dietary
and NTBC treatments of HT1 patients are likely to have
varied, to some extent, between different clinical centres,
and the exact treatment histories could not be taken into
account in the present study. Further subgroup analyses,
comparing different groups based on the age at diagnosis
and clinical symptoms at diagnosis, did not reveal any
Fig. 3 Performance on two different constructs of social cognition expressed as percentage of errors on face recognition a and the identification
of facial emotions b comparing HT1 patients and healthy controls. *p < 0.05, **p < 0.01
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significant differences, although this may, in part, be ex-
plained by the small group sizes.
Our results support and extend previous findings of
suboptimal neurocognitive outcome in HT1 [6–10].
Despite using only two subtests of the WISC/WAIS to
broadly estimate IQ, clear differences were observed,
with HT1 patients performing significantly worse than
controls. While IQ is a broad construct measuring intel-
lectual functioning in general, HT1 patients performed
worse than controls on most measures of EF and social
cognition as well. “Pure” social cognition was measured
in the IFE-task and the relatively easy task part 1 of the
FR-task. The more difficult parts of this task require, in
addition to social cognition, the EF working memory
[27]. Our results showed differences in tasks or task
parts measuring relatively “pure” social cognition, tasks
or task parts measuring “pure” EF and those measuring
combinations of social cognition and EF.
In order to investigate the clinical importance of these
significant results, Z-scores were calculated to see how
many patients score within or outside the normal range.
In most of the tasks measuring IQ, EF and social cogni-
tion many patients scored below the normal range. This
may be interpreted as support for the case that these re-
sults have clinical relevance as well.
Several hypotheses have been proposed to explain the
suboptimal neuropsychological outcome in HT1
patients, but the mechanism remains unknown. First of
all, the fact that neuropsychological impairment was ob-
served after the introduction of NTBC may suggest a
possible direct association between these deficiencies
and NTBC. However, developing severe liver disease of
any cause, especially in infancy, is associated with both a
low life expectancy and a risk of long term developmen-
tal sequelae and behavioural consequences [28]. There-
fore, the low life expectancy in these HT1 patients, if
not treated with NTBC, may have masked the impaired
neurocognitive outcome associated with liver dysfunc-
tion in HT1. Our results did not show significant differ-
ences between the patients presenting with and without
liver dysfunction, making the latter hypothesis of liver
dysfunction in early life causing the developmental prob-
lems less likely.
On the other hand the duration of treatment with
NTBC was negatively correlated to the IQ. This could
indicate a possible direct effect of NTBC on the cogni-
tive outcome. However, NTBC may have induced neuro-
cognitive impairments through its effect on blood
phenylalanine and tyrosine concentrations as well. With
NTBC treatment, tyrosine concentrations increase even
without liver failure, leading to the hypothesis that high
tyrosine concentrations may be associated with impaired
neurocognitive functioning. High tyrosine concentra-
tions could have a direct toxic effect on the brain,










Tasks RT (s) Errors (%) RT (s) Errors (%) RT (s) Errors (%) RT (s) Errors (%)
SSV-inhibition (n = 19)
Median Z-score −0.15 −0.11 −0.32 −0.49 0.64 0.82 −0.15 0.27
Z-score > +2 (n) 1 1 1 1 0 0 2 2
SSV-Cog. Flex. (n = 19)
Median Z-score 0.78 1.53 −0.17 0.67 0.54 −0.85 0.39 1.43
Z-score > +2 (n) 3 3 0 1 0 1 3 5
MS2D (n = 17)
Median Z-score 1.43 −0.07 1.38 −0.35 1.10 1.54 1.12 −0.09
Z-score > +2 (n) 3 1 2 0 1 1 6 2
FI (n = 18)
Median Z-score 0.50 0.52 0.50 0.30 0.36 1.23 0.45 0.52
Z-score > +2 (n) 1 1 1 1 1 0 3 2
FR-overall (n = 18)
Median Z-score 1.14 1.80 0.34 1.36 −0.41 1.53 0.39 1.57
Z-score > +2 (n) 2 3 0 2 1 1 3 6
IFE-overall (n = 17)
Median Z-score 0.29 0.67 −0.21 1.03 2.74 0.46 0.03 0.55
Z-score > +2 (n) 1 2 0 1 2 0 3 3
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similar to high phenylalanine concentrations in PKU
[29, 30]. In Tyrosinemia type II, biochemically charac-
terized by high blood tyrosine and normal blood
phenylalanine concentrations, neurocognitive deficien-
cies have been shown as well. Especially when dietary
treatment is started late, these patients are prone to
cognitive deficiencies possibly caused by high tyrosine
concentrations [31].
In PKU, research has suggested the presence of additional
pathophysiological mechanisms, next to phenylalanine tox-
icity, affecting brain functioning. For example, high blood
phenylalanine concentrations may inhibit the transport of
the other large neutral amino acids (LNAA) into the brain,
due to competitive transport across the blood–brain barrier
[30]. Impaired transport of those LNAA into the brain
could influence protein and neurotransmitter synthesis in
the brain [29, 30]. In HT1 patients, there could also be an
impaired influx of LNAAs, but this time caused by an
excess of the LNAA tyrosine, which is the metabolic
precursor of dopamine. Evidence for abnormalities in
neurotransmitter synthesis in HT1 stems from studies
showing low cerebral spinal fluid (CSF) concentrations
of serotonin and high to normal CSF dopamine con-
centrations in HT1 patients [32], both possibly related
to the high blood tyrosine concentrations. High blood
tyrosine concentrations may cause low CSF serotonin
levels by blocking the transport of its metabolic pre-
cursor, the LNAA tryptophan, across the blood–brain
barrier. At the same time, high blood tyrosine concen-
trations may cause a high influx of tyrosine into the
brain causing higher-than-normal CSF dopamine
levels. Very low phenylalanine levels in HT1 patients
could be important as well. It has been reported that
very low phenylalanine levels could have peripheral
implications such as eczema and faltering growth, but
could also cause developmental delay in HT1 [19].
Low phenylalanine concentrations are sometimes seen
in HT1 patients [7, 18, 19]. Thus, both high tyrosine
and low phenylalanine concentrations may be important in
the cascade ultimately leading to brain dysfunction in HT1.
Therefore, future studies have to relate the neuropsycho-
logical outcome to treatment parameters such as tyrosine
and phenylalanine concentrations throughout life. In
addition to this, a direct effect of NTBC on the neurocogni-
tive outcome needs further investigation.
Conclusions
HT1 patients on average underperformed on the neuro-
cognitive tasks compared to healthy controls when
examining IQ, EF, and social cognition. The patho-
physiological mechanisms that result in this brain dys-
function are not fully understood yet. Clearly, possible
similarities between HT1 and other single amino acid
disorders such as PKU could help to elucidate these
mechanisms. Future research into HT1 should also com-
pare the neuropsychological outcome between HT1 pa-
tients with different treatment regimes. Moreover, future
studies should focus on the pathophysiological mecha-
nisms underlying the impairments. This combined
knowledge will contribute to further optimization of the
treatment strategies for HT1 patients.
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